Annual CFF
$6.64 M
-$14.09 M-67.98%
31 December 2023
Summary:
Fennec Pharmaceuticals annual cash flow from financing activities is currently $6.64 million, with the most recent change of -$14.09 million (-67.98%) on 31 December 2023. During the last 3 years, it has fallen by -$25.65 million (-79.44%). FENC annual CFF is now -79.44% below its all-time high of $32.29 million, reached on 31 December 2020.FENC Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$528.00 K
-$785.00 K-305.45%
30 September 2024
Summary:
Fennec Pharmaceuticals quarterly cash flow from financing activities is currently -$528.00 thousand, with the most recent change of -$785.00 thousand (-305.45%) on 30 September 2024. Over the past year, it has dropped by -$729.00 thousand (-362.69%). FENC quarterly CFF is now -101.65% below its all-time high of $31.94 million, reached on 30 June 2020.FENC Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$4.33 M
-$729.00 K-14.42%
30 September 2024
Summary:
Fennec Pharmaceuticals TTM cash flow from financing activities is currently $4.33 million, with the most recent change of -$729.00 thousand (-14.42%) on 30 September 2024. Over the past year, it has increased by +$2.60 million (+149.83%). FENC TTM CFF is now -86.60% below its all-time high of $32.29 million, reached on 31 December 2020.FENC TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FENC Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -68.0% | -362.7% | +149.8% |
| 3 y3 years | -79.4% | -100.0% | -20.3% |
| 5 y5 years | +182.8% | -100.0% | +287.7% |
FENC Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -79.4% | +33.4% | -102.7% | +53.4% | -79.8% | +5994.4% |
| 5 y | 5 years | -79.4% | +9449.3% | -101.7% | +53.4% | -86.6% | +6194.4% |
| alltime | all time | -79.4% | +9449.3% | -101.7% | +53.4% | -86.6% | +2691.0% |
Fennec Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$528.00 K(-305.4%) | $4.33 M(-14.4%) |
| June 2024 | - | $257.00 K(-122.7%) | $5.06 M(-4.8%) |
| Mar 2024 | - | -$1.13 M(-119.8%) | $5.31 M(-20.0%) |
| Dec 2023 | $6.64 M(-68.0%) | $5.73 M(+2750.7%) | $6.64 M(+283.3%) |
| Sept 2023 | - | $201.00 K(-60.9%) | $1.73 M(-91.9%) |
| June 2023 | - | $514.00 K(+166.3%) | $21.38 M(+2.2%) |
| Mar 2023 | - | $193.00 K(-76.6%) | $20.91 M(+0.9%) |
| Dec 2022 | $20.73 M(+316.5%) | $824.00 K(-95.8%) | $20.73 M(+4.1%) |
| Sept 2022 | - | $19.85 M(>+9900.0%) | $19.92 M(>+9900.0%) |
| June 2022 | - | $46.00 K(+206.7%) | $71.00 K(-98.6%) |
| Mar 2022 | - | $15.00 K(+50.0%) | $4.99 M(+0.3%) |
| Dec 2021 | $4.98 M(-84.6%) | $10.00 K(>+9900.0%) | $4.98 M(-8.3%) |
| Sept 2021 | - | $0.00(-100.0%) | $5.43 M(+2.2%) |
| June 2021 | - | $4.97 M(>+9900.0%) | $5.31 M(-83.5%) |
| Mar 2021 | - | $0.00(-100.0%) | $32.29 M(0.0%) |
| Dec 2020 | $32.29 M(<-9900.0%) | $462.00 K(-494.9%) | $32.29 M(+1.5%) |
| Sept 2020 | - | -$117.00 K(-100.4%) | $31.83 M(-0.4%) |
| June 2020 | - | $31.94 M(>+9900.0%) | $31.94 M(<-9900.0%) |
| Dec 2019 | -$71.00 K(-103.0%) | $0.00(0.0%) | -$71.00 K(-106.4%) |
| Sept 2019 | - | $0.00(0.0%) | $1.12 M(-30.2%) |
| June 2019 | - | $0.00(-100.0%) | $1.60 M(-23.5%) |
| Mar 2019 | - | -$71.00 K(-106.0%) | $2.09 M(-11.0%) |
| Dec 2018 | $2.35 M(-91.6%) | $1.19 M(+145.8%) | $2.35 M(-88.9%) |
| Sept 2018 | - | $483.00 K(-1.6%) | $21.05 M(+0.3%) |
| June 2018 | - | $491.00 K(+164.0%) | $20.98 M(-25.5%) |
| Mar 2018 | - | $186.00 K(-99.1%) | $28.16 M(+0.7%) |
| Dec 2017 | $27.98 M(+447.7%) | $19.89 M(+4704.8%) | $27.98 M(+246.1%) |
| Sept 2017 | - | $414.00 K(-94.6%) | $8.08 M(+5.4%) |
| June 2017 | - | $7.67 M(>+9900.0%) | $7.67 M(+53.2%) |
| Mar 2017 | - | $0.00(0.0%) | $5.01 M(-2.0%) |
| Dec 2016 | $5.11 M(+927.8%) | $0.00(0.0%) | $5.11 M(0.0%) |
| Sept 2016 | - | $0.00(-100.0%) | $5.11 M(-0.4%) |
| June 2016 | - | $5.01 M(+4807.8%) | $5.13 M(+796.7%) |
| Mar 2016 | - | $102.00 K(>+9900.0%) | $572.00 K(+15.1%) |
| Dec 2015 | $497.00 K(-78.8%) | $0.00(-100.0%) | $497.00 K(-81.4%) |
| Sept 2015 | - | $21.00 K(-95.3%) | $2.68 M(0.0%) |
| June 2015 | - | $449.00 K(+1563.0%) | $2.68 M(+15.6%) |
| Mar 2015 | - | $27.00 K(-98.8%) | $2.32 M(-1.1%) |
| Dec 2014 | $2.34 M(+49.2%) | $2.18 M(>+9900.0%) | $2.34 M(+35.4%) |
| Sept 2014 | - | $21.00 K(-75.9%) | $1.73 M(+1.2%) |
| June 2014 | - | $87.00 K(+64.2%) | $1.71 M(+5.4%) |
| Mar 2014 | - | $53.00 K(-96.6%) | $1.62 M(+3.4%) |
| Dec 2013 | $1.57 M(>+9900.0%) | $1.57 M(>+9900.0%) | $1.57 M(>+9900.0%) |
| Sept 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2012 | - | $0.00(0.0%) | $2.57 M(0.0%) |
| Dec 2011 | $2.57 M(-64.3%) | $0.00(0.0%) | $2.57 M(0.0%) |
| Sept 2011 | - | $0.00(-100.0%) | $2.57 M(0.0%) |
| June 2011 | - | $2.57 M(>+9900.0%) | $2.57 M(-64.3%) |
| Mar 2011 | - | $0.00(0.0%) | $7.19 M(0.0%) |
| Dec 2010 | $7.19 M(>+9900.0%) | $0.00(0.0%) | $7.19 M(0.0%) |
| Sept 2010 | - | $0.00(-100.0%) | $7.19 M(0.0%) |
| June 2010 | - | $7.19 M(>+9900.0%) | $7.19 M(>+9900.0%) |
| Mar 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2009 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2009 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2009 | - | $0.00(0.0%) | $7000.00(0.0%) |
| Dec 2008 | $7000.00(-100.0%) | $0.00(-100.0%) | $7000.00(-121.2%) |
| Sept 2008 | - | $7000.00(>+9900.0%) | -$33.00 K(-17.5%) |
| June 2008 | - | $0.00(0.0%) | -$40.00 K(-106.3%) |
| Mar 2008 | - | $0.00(-100.0%) | $638.00 K(-97.3%) |
| Dec 2007 | $23.88 M(+294.4%) | -$40.00 K(<-9900.0%) | $23.88 M(-0.2%) |
| Sept 2007 | - | $0.00(-100.0%) | $23.91 M(+0.1%) |
| June 2007 | - | $678.00 K(-97.1%) | $23.90 M(-18.3%) |
| Mar 2007 | - | $23.24 M(>+9900.0%) | $29.26 M(+383.4%) |
| Dec 2006 | $6.05 M(-23.9%) | $0.00(-100.0%) | $6.05 M(+0.3%) |
| Sept 2006 | - | -$15.00 K(-100.2%) | $6.04 M(-57.4%) |
| June 2006 | - | $6.04 M(>+9900.0%) | $14.18 M(+74.0%) |
| Mar 2006 | - | $27.00 K(-273.1%) | $8.15 M(+2.4%) |
| Dec 2005 | $7.96 M(-67.6%) | -$15.60 K(-100.2%) | $7.96 M(-0.2%) |
| Sept 2005 | - | $8.13 M(>+9900.0%) | $7.97 M(-4875.2%) |
| June 2005 | - | $9000.00(-105.5%) | -$167.00 K(-102.1%) |
| Mar 2005 | - | -$163.00 K(+1153.8%) | $7.89 M(-67.7%) |
| Sept 2004 | - | -$13.00 K(-100.2%) | $24.39 M(-0.7%) |
| June 2004 | $24.56 M(+1166.5%) | $8.06 M(-1666.9%) | $24.56 M(+33.3%) |
| Mar 2004 | - | -$514.70 K(-103.1%) | $18.43 M(-2.7%) |
| Dec 2003 | - | $16.85 M(>+9900.0%) | $18.95 M(+800.9%) |
| Sept 2003 | - | $158.40 K(-91.8%) | $2.10 M(+8.5%) |
| June 2003 | $1.94 M(-5976.4%) | $1.94 M(>+9900.0%) | $1.94 M(>+9900.0%) |
| Mar 2003 | - | $4000.00(-31.0%) | $2800.00(-333.3%) |
| Dec 2002 | - | $5800.00(-200.0%) | -$1200.00(-96.4%) |
| Sept 2002 | - | -$5800.00(+383.3%) | -$32.90 K(-0.3%) |
| June 2002 | -$33.00 K(-100.3%) | -$1200.00(<-9900.0%) | -$33.00 K(+3.8%) |
| Mar 2002 | - | $0.00(-100.0%) | -$31.80 K(0.0%) |
| Dec 2001 | - | -$25.90 K(+339.0%) | -$31.80 K(+439.0%) |
| Sept 2001 | - | -$5900.00 | -$5900.00 |
| June 2001 | $12.25 M(+857.0%) | - | - |
| June 2000 | $1.28 M | - | - |
FAQ
- What is Fennec Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual CFF year-on-year change?
- What is Fennec Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly CFF year-on-year change?
- What is Fennec Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals TTM CFF year-on-year change?
What is Fennec Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of FENC is $6.64 M
What is the all time high annual CFF for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual cash flow from financing activities is $32.29 M
What is Fennec Pharmaceuticals annual CFF year-on-year change?
Over the past year, FENC annual cash flow from financing activities has changed by -$14.09 M (-67.98%)
What is Fennec Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of FENC is -$528.00 K
What is the all time high quarterly CFF for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly cash flow from financing activities is $31.94 M
What is Fennec Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, FENC quarterly cash flow from financing activities has changed by -$729.00 K (-362.69%)
What is Fennec Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of FENC is $4.33 M
What is the all time high TTM CFF for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high TTM cash flow from financing activities is $32.29 M
What is Fennec Pharmaceuticals TTM CFF year-on-year change?
Over the past year, FENC TTM cash flow from financing activities has changed by +$2.60 M (+149.83%)